Will Travere’s Removal From Key Russell Value Indices Change Travere Therapeutics’ (TVTX) Narrative?

• In late June 2026, Travere Therapeutics, Inc. was removed from several major Russell value and small-cap benchmarks, including the Russell 2000 Value, Russell 3000 Value, Russell 2500 Value, Russell Small Cap Comp Value, and Russell 3000E Value indices.
• This broad index removal can prompt forced portfolio rebalancing by index-tracking funds, potentially shifting how institutional investors assess Travere’s role in diversified healthcare portfolios.
• We’ll now examine how Travere’s removal from multiple Russell value and small-cap indices could reshape its investment narrative and risk profile.

The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Travere Therapeutics Investment Narrative Recap

To own Travere today, you likely need to believe FILSPARI can anchor a focused rare kidney disease franchise while the company manages ongoing losses and high R&D spend. The broad Russell index removals in late June 2026 may affect trading and visibility, but they do not directly change FILSPARI’s near term label, uptake, or regulatory path, so the core catalyst and key execution risks remain essentially intact for now.

The most relevant recent announcement is the April 2026 FDA approval of FILSPARI to reduce proteinuria in adults and children 8 and older with FSGS without nephrotic syndrome. That expanded indication directly supports Travere’s central growth driver at the same time the stock exits several value and small cap indices, sharpening the contrast between operational progress on the drug franchise and evolving perceptions of the shares in diversified portfolios.

Yet, while FILSPARI’s momentum matters, investors should also be aware of the increasing risk that payer scrutiny and drug pricing pressure could…

Read the full narrative on Travere Therapeutics (it’s free!)

Travere Therapeutics’ narrative projects $1.3 billion revenue and $323.5 million earnings by 2029.

Uncover how Travere Therapeutics’ forecasts yield a $58.36 fair value, in line with its current price.

Exploring Other Perspectives

By contrast, the most optimistic analysts were once modeling around US$1.7 billion of revenue and over US$500 million of earnings by 2029, so if you believed that kind of upside before Travere’s index removal, it is worth asking whether concentrated FILSPARI dependence still feels as comfortable now.

Explore 6 other fair value estimates on Travere Therapeutics – why the stock might be worth as much as 57% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they’re targeting before they’ve flown the coop:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]